The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer

• Ovarian cancer is the most lethal among gynecological cancers. • Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients. • Almost one every three patients treated with carboplatin experiences hypersensitivity reactions. • Patients may experience breakt...

Descripción completa

Detalles Bibliográficos
Autores principales: Vultaggio, Alessandra, Petrella, Maria Cristina, Tomao, Federica, Nencini, Francesca, Mecheri, Valentina, Marini, Andrea, Perlato, Margherita, Vivarelli, Emanuele, De Angelis, Claudia, Ferrarini, Ilaria, Pillozzi, Serena, Matucci, Andrea, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651898/
https://www.ncbi.nlm.nih.gov/pubmed/34926761
http://dx.doi.org/10.1016/j.gore.2021.100880
_version_ 1784611485058596864
author Vultaggio, Alessandra
Petrella, Maria Cristina
Tomao, Federica
Nencini, Francesca
Mecheri, Valentina
Marini, Andrea
Perlato, Margherita
Vivarelli, Emanuele
De Angelis, Claudia
Ferrarini, Ilaria
Pillozzi, Serena
Matucci, Andrea
Antonuzzo, Lorenzo
author_facet Vultaggio, Alessandra
Petrella, Maria Cristina
Tomao, Federica
Nencini, Francesca
Mecheri, Valentina
Marini, Andrea
Perlato, Margherita
Vivarelli, Emanuele
De Angelis, Claudia
Ferrarini, Ilaria
Pillozzi, Serena
Matucci, Andrea
Antonuzzo, Lorenzo
author_sort Vultaggio, Alessandra
collection PubMed
description • Ovarian cancer is the most lethal among gynecological cancers. • Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients. • Almost one every three patients treated with carboplatin experiences hypersensitivity reactions. • Patients may experience breakthrough reactions during drug desensitization. • Omalizumab represents a promising new treatment to overcome carboplatin hypersensitivity.
format Online
Article
Text
id pubmed-8651898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86518982021-12-17 The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer Vultaggio, Alessandra Petrella, Maria Cristina Tomao, Federica Nencini, Francesca Mecheri, Valentina Marini, Andrea Perlato, Margherita Vivarelli, Emanuele De Angelis, Claudia Ferrarini, Ilaria Pillozzi, Serena Matucci, Andrea Antonuzzo, Lorenzo Gynecol Oncol Rep Case Reports and Case Series • Ovarian cancer is the most lethal among gynecological cancers. • Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients. • Almost one every three patients treated with carboplatin experiences hypersensitivity reactions. • Patients may experience breakthrough reactions during drug desensitization. • Omalizumab represents a promising new treatment to overcome carboplatin hypersensitivity. Elsevier 2021-10-12 /pmc/articles/PMC8651898/ /pubmed/34926761 http://dx.doi.org/10.1016/j.gore.2021.100880 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Reports and Case Series
Vultaggio, Alessandra
Petrella, Maria Cristina
Tomao, Federica
Nencini, Francesca
Mecheri, Valentina
Marini, Andrea
Perlato, Margherita
Vivarelli, Emanuele
De Angelis, Claudia
Ferrarini, Ilaria
Pillozzi, Serena
Matucci, Andrea
Antonuzzo, Lorenzo
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title_full The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title_fullStr The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title_full_unstemmed The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title_short The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
title_sort anti-ige monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
topic Case Reports and Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651898/
https://www.ncbi.nlm.nih.gov/pubmed/34926761
http://dx.doi.org/10.1016/j.gore.2021.100880
work_keys_str_mv AT vultaggioalessandra theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT petrellamariacristina theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT tomaofederica theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT nencinifrancesca theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT mecherivalentina theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT mariniandrea theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT perlatomargherita theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT vivarelliemanuele theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT deangelisclaudia theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT ferrariniilaria theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT pillozziserena theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT matucciandrea theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT antonuzzolorenzo theantiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT vultaggioalessandra antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT petrellamariacristina antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT tomaofederica antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT nencinifrancesca antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT mecherivalentina antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT mariniandrea antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT perlatomargherita antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT vivarelliemanuele antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT deangelisclaudia antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT ferrariniilaria antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT pillozziserena antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT matucciandrea antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer
AT antonuzzolorenzo antiigemonoclonalantibodyomalizumabasadjuvanttreatmentindesensitizationtocarboplatininpatientswithovariancancer

Ejemplares similares